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	Immunology Behind The Filler 
 
 
Introduction: All injected filler may cause foreign body granulomas in some patient. 
Fillers as an antigen and our immune system play a rule of granuloma formation. 
Larger microspheres fillers with irregular surface can not be phagocytized will 
encapsulated with fibrous tissue   
Method: we measures the immunology of the patient  with silicone injection. We  
measured inflammation cytokines such as TNF α, IFN γ, and  Anti inflammation or 
immune tolerance marker such as IL-10, IDO, CD4CD25. We took the blood from 
the patient and chin granuloma as tissue from the injection site, also submental skin as 
skin surround the injection site. 
Result: In this study showed the cytokines which produced by macrophages and 
indoleamine 2,3-dioxygenase (IDO) as immune tolerance play the rule of granuloma 
formation.  
Conclusion : Immune tolerance system  played the rule of granuloma formation due 
to silicone injection. 
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1. BACKGROUND 
The result of Indonesian Association of Plastic Surgeons survey done during 2004-2007, found 249 
cases of silicone complications.1  Epidemiological data in other countries were not clear because silicone 
injection had been banned. In 1990, more than 100,000 patients in United States had received silicone 
injection in their face.2 There have been numerous case reports documenting the consequences of 
silicone filler, both domestic and overseas reports.2-5 
The use of silicone filler injection for cosmetic treatment had been banned by Federal Food, Drug & 
Cosmetic America (FDA) since 1992.2 Liquid silicone which was injected into the skin can migrate and 
cause morphological changes and uncontrolled inflammatory response. Liquid silicone in the tissue is 
persistent, so it will lead to chronic inflammation and granulomas formation. In severe cases, it could 
be followed by infection, necrosis, and abscess.3,5-6 
 
 
The pathogenesis of granuloma formation due to silicone injection might be explained by the new 
theory of immune tolerance  which is played by Indoleamine-2,3-dioxygenase enzyme (IDO),  and IL-
10.  
 
Until now, the pathogenesis of silicone granuloma has been studied, but the results are still 
controversial. Silicone granuloma was difficult to evacuate and is still able to form new granuloma after 
the evacuation. The  aim of this study was to analyze the pathogenesis of silicone granuloma including 
its correlation with immune inflammatory responses and tolerance. The present study is a continuation 
of a study on classification of foreign body reaction due to industrial silicone injection, which has been 
published in Dermatologic Surgery Journal, volume 44, number 9, September 2018.       
       
2.  METHOD OF STUDY 
Control group consisted subjects with 37 normal skins who had face lift surgery of the same age and 
sex. All tissues were examined histopathologically (HE staining) for evaluating the degree of foreign 
body reaction (FBR) ( it had been reported in the Dermatologic Surgery Journal , volume 44. Number 
9, September, 2018).  Laboratory experimental study was also performed to assess blood cytokine 
levels by (a) culturing whole blood cells from granuloma patient and normal individuals, using Roswell 
Park Memorial Institute (RPMI) medium. The RPMI was stimulated by phytohemagglutinin (PHA) and 
3% of industrial-grade silicone; (b) examining cytokine levels from cell culture supernatant on day 3, 
which included TNF-α, IFN-γ, and IL-10. All of the cytokines were analyzed using Luminex and IDO 
with ELISA.  
In accordance to the aim of the study, a statistical test was carried out using SPSS version 16.  For 
numerical data, univariate and bivariate analysis were performed, in which normality test was 
performed in order to determine to use either parametric or non-parametric test. Categorization of 
numerical data was made based on cut-off point, which was analyzed using receiver operator curve 
(ROC) test.   
 
3.  RESULTS 
Subject characteristics  
The present study is a continuation of our previous study, i.e. the classification of foreign body reaction 
due to Industrial silicone injection; therefore, it has the same characteristics of subjects with the 
previous study.  
 
Results of our history taking in 31 patients with granuloma due to silicone injection on their skin 
revealed that they usually had the injection at beauty salon. In general, the symptoms of granuloma 
occurred at approximately 12.5 years after the injection; while skin deformation took place at the 4th 
year, which preceded discoloration occurring at the 5th year. Silicone injections were mainly done on 
nose and chin regions and 54.8% of the patients who had complication due to silicone injection did not 
know that the injected material was silicone.  
TABLE 1. Clinical Examination, Onset of Granuloma Symptoms, and Silicone 
Concentration for Subjects of Different Age Categories 
 
X, mean; clinical examination, graded granuloma by clinical examination. Mild, nodule <3 cm; moderate, nodule 3 to 6 cm, or 
nodule <6 cm with redness <3 cm; severe, nodule expanding out of the chin or redness >3 cm. Onset of granuloma symptoms: 
time from injection of the silicone to time when patient complains about the symptom or comes to visit the doctor 
     
 Variables Normal Control Chin Granuloma Submental Skin 
  Group (n = 37) Group (n = 31) Group (n = 31) 
  
47 (28–55) 40.1 + 8.78 40.1 + 8.78 
 
 Age (yr), X + SD 
 
 Clinical examination, %    
 
 Mild  6 (19.4%)  
 
 Moderate  18 (58.1%)  
 
 Severe  7 (22.6%)  
 
 Onset of granuloma symptom (yr)  12.5 + 5.5 12.5 + 5.5 
 
 Silicone concentration (mg/g), median 0 (0–253) 688 (4.1–10,430) 944 (0–6,065) 
 (minimum–maximum)    
 
The silicone levels in submental skin were significantly higher than those in granuloma tissue (688mcg/g 
(4.1-10430) vs. 944 mcg/g (0-6065)). Another interesting finding was that silicone is also found in 
normal skin tissue with approximate level of 44.07mcg/g.  
Hitherto there has been no finding or study on normal silicone level in skin tissues of female individuals. 
Results of the present study were new findings. It can be used as a reference; when the silicone levels 
are higher than the reference, health problems may occur, which presumably may be caused by intake 
of silicone substance contained in cosmetic product.16 (It has been published in Journal of Pakistan 
Association of Dermatologists. 2018) 
 
 
The characteristics of immune response in the blood of normal and granuloma group  
 
The action of injecting silicone filler (foreign body) into body tissue will induce immune response, both 
cellular and humoral responses. Large-sized silicone can not be completely destroyed by the 
phagocytes, such as the macrophages; therefore, the foreign body will remain and cause chronic 
inflammation. In some individuals, the reaction induces the development of granuloma. The 
pathogenesis of granuloma is categorized into two types, which are type 1 and type 2 depending on 
the type of T-helper cells (Th) that have roles in immune response.12,24 Th1 releases proinflammatory 
cytokines, i.e. TNF-a, IFN-g, IL-2 and Th2 releases anti-inflammatory cytokines, i.e. IL-10, TGF-b, IL-
4.8 
 
Advanced science in immunology has recently revealed that T cells subpopulation, i.e. T regulator 
(CD4+CD25+) and its product of IL10 and TGF-β cytokines have important role in controlling the activity 
of both Th1 and Th2 cells. Indoleamine 2,3 dioxygenase (IDO) enzyme, which is released by the antigen 
presenting cell (APC) will help Treg cells in the process of immune balance, homeostasis and tolerance 
as well as determining the occurring immune response.12,13 Treg cells, IL-10, IDO enzyme will inhibit 
inflammation, which occurs due to foreign body reaction (FBR).  
 
In normal patients and those with granuloma, there was no significant difference regarding the levels 
of TNF-α, IFN-γ, IL-10 cytokines and IDO of blood culture supernatant, which was stimulated by 3% 
silicone compared with the negative control (RPMI blood). A significant difference was only found 
between the negative and positive controls (PHA), (p < 0.001). Table 2. 
 
The level of TNF-α cytokine in patients with silicone granuloma was significantly different from normal 
patients. (p=0.021). The level of IDO enzyme in patients with silicone granuloma was significantly 
different from normal patients. (RPMI: p=0.049; silicone p=0.05). 
Patients in silicone granuloma group had higher TNF-α inflammatory cytokine level than normal group; 
however, their anti-inflammatory or immune tolerance and IDO enzyme levels were lower than normal 
(Table 2) 
 
Table 2.  Correlation of TNF-α, IFN-γ, IL-10, IDO cytokine levels in blood culture 
supernatant of PHA, RPMI and silicone between the normal and granuloma groups 
 
Types of cytokines 
 
Cytokines levels in normal 
group 
Cytokines levels in 
granuloma group 
    P value 
                Types of  
                culture 
n=31 n=31  
         
TNF-α 
pg/mL 
PHA 757.51 (24.6-13274.3) 2689.61 (29.5-7573.6) p= 0.056m 
RPMI 91.62 (21.9-1253.8) 185.10 (23.5-1469.4) p= 0.021m* 
Silicone  73.99 (22.8-3710) 127.06 (18.1-2910.45) p= 0.100m 
            
IFN-γ 
pg/mL 
PHA 372.36 (27.1-52503.7) 6868.31 (12.5-81372.5) p= 0.075m 
RPMI 84.45 (6.6-864.9) 175.38 (9-5329.45) p= 0.304m 
Silicone 37.83 (5.7-12736.8) 169.40 (21.3-1021.5) p= 0.310m 
            
IL-10 
pg/mL 
PHA 191.6 (10.2-927) 192.94 (13.6-890.4) p= 0.392m 
RPMI 23.1 (8.6-112.6) 17.6 (6.5-418.5) p= 0.207m 
Silicone 22.4 (8.6-417.4) 17.13 (6.1-339.95) p= 0.281m 
                 
IDO 
ng/mL 
PHA 1112.7 (92.1-7146.7) 979.39 (106.7-7366.7) p= 0.449m 
RPMI 784.2 (92.1-6280) 458.2 (97-6440) p= 0.049m* 
Silicone 773.1 (66.7-5106.7) 471.51 (100.6-5600) p= 0.050m* 
TNF-α/ 
IL-10 ratio 
PHA 7.6 (0.3-32) 10.7 (1-60.9) p= 0.055m 
RPMI 3.8 (0.3-27.9) 10.6 (0.2-63) p= 0.002m* 




PHA 0.7 (0-5.9) 3.2 (0.0-14.5) p= 0.008m* 
RPMI 0.1 (0-5.2) 0.33 (0-12.0) p= 0.008m* 
Silicone 0.11 (0-7.0) 0.17 (0-12.2) p= 0.026m* 
                  Note:                
                  PHA: phytohemaglutinin,  RPMI: culture using the Roswell park memorial institute         
                   medium / normal serum; Silicone: 3% industrial silicone. 
                            mMann Whitney test,   ng/mL:nanogram/mililiter, pg:pikogram/ mililiter.  
                  All the above mentioned data were median values (minimum-maximum). 
                  *significant at p £0.05, **very significant at p £0.005 
 
From those data results, it is assumed that the development of granuloma in the case group was 
associated with excessive inflammatory response (TNF-α) when there was silicone-induced stimulation, 
which had not been balanced out by adequate immune tolerance.  
 
The potency of immune tolerance in the present study was evaluated based on anti-inflammatory 
mediators, i.e. IL-10 and IDO enzyme. In order to find further answer for the assumption, data analysis 
was continued by calculating the ratios of expression on levels of proinflammatory cytokines (TNF-α 
and IFN-γ) to the capacity of expressing anti-inflammatory tolerance mediators, i.e. IL-10 and IDO 
enzyme for each subject in the case group and normal control group.  
 
The greater the ratio, the stronger the behavior of immune cells producing inflammatory mediators or 
the weaker the capacity of immune cells that mediating immune tolerance. Results of analysis are listed 
in Table 1, which shows that the TNF-α/IL10 ratio and TNF-α/IDO ratio, both in RPMI-, PHA- and 
silicone-stimulated cultures, nearly significantly higher in all subjects of granuloma group compared to 
the control group. Such result has answered the assumption and confirmed that individuals with 
granuloma due to silicone injections is a group of subjects who has immune cells expressing high pro-
inflammatory cytokine levels; however, it is not followed by adequate capacity of producing anti-
inflammatory cytokines when being stimulated by silicone. 
 
Predicting the development of granuloma based on cytokine levels in blood culture 
supernatant 
Based on the results of the present study, the levels of TNF-α in RPMI blood culture supernatant had a 
significant correlation with the expression of TNF-α in granuloma. Each increased level of TNF-α in 
blood culture supernatant would be followed by increased TNF-α expression in granuloma tissue. The 
level of TNF-a in blood culture supernatant was inversely correlated with the development of granuloma 
disorder (p =  0.003, r = -0.516). It is concluded that TNF-α has systemic effect. The level of TNF-a in 
blood culture supernatant can be used to predict immune response that may lead to the development 
of granuloma.   
 
The development of granuloma is affected by pro-inflammatory cytokines (TNF-α) and body tolerance 
and the role is played by IL-10 and IDO enzyme. To evaluate a more accurate prediction, a ratio of 
pro-inflammatory to anti-inflammatory or tolerance should be made. Results on TNF-a/IL-10 ratio, TNF-
a/IDO ratio and the duration of developing symptoms can be seen in Table 3. 
 
 
Table 3.  Correlation of TNF-a/IL-10 ratio and TNF-a/IDO ratio with duration of 



























s  Spearman test ; * significant at p £0.05, power of correlation (r) 0.00 -0.199 very weak, 0.20-0.399 
weak, 0.40-0.599 moderate, 0.60-0.799 strong, 0.80-1.00 very strong. R2: the coefficient of 
determination. 
In table 3, RPMI TNF-α/IL-10 ratio inversely correlated with the duration of developing granuloma 
symptoms. (p=0.038s*, r=-0.374). RPMI TNF-α/IL-10  ratio can be explained by duration of developing 
granuloma symptoms as many as 14 % (R2=0.140).  
 
RPMI TNF-α/IDO ratio inversely correlated with the duration of developing granuloma symptoms. 
(p=0.028s*, r=-0.395). RPMI TNF-α/IDO ratio can be explained by duration of developing granuloma 
symptoms as many as 15.6 % (R2=0.156). 
 
    p=0.028* r= -0.395 
Figure 1.  Correlation of TNF-α/IDO ratio in RPMI blood culture supernatant with 
duration of developing granuloma symptoms 
  
Note: * significant p= £0.05, duration of time in years 
In Figure 1, TNF-α/IDO ratio in RPMI blood culture supernatant inversely correlated with duration of 
developing symptoms. TNF-α/IDO ratio and TNF-α/IL-10 ratio in blood culture supernatant can serve 
as the basics for predicting the development of granuloma. For normal patient, a cut-off point should 
be determined before silicone injection is performed. The cut-off value was obtained from the data of 
granuloma patients, i.e. the median of RPMI TNF-a/IL-10 ratio (10.6) and RPMI TNF-a/IDO ratio 
(0.3).(Table 2) 
Cut-off points obtained from the data of normal patients group, i.e. median value, were used as the 
basic management of patients that had received silicone injection and it served as the lower save limit, 
i.e. levels of RPMI TNF-a/IL-10 ratio (3.8) and RPMI TNF-a/IDO ratio (0.1). (Table 2) 
 
4.  DISCUSSION 
Immune response of silicone granuloma in blood culture supernatant 
Silicone is a non-biodegradable molecule; therefore, it continues to exist in body tissue when it is 
injected. Silicone in the tissue has hydrophobic interaction with blood protein, which will initiate the 
process of clotting, fibrinolytic and activation of complement and kinin systems. As it contains various 
cytokines, chemokines and growth factors on matrix protein of silicone or biomaterial surface, it causes 
activation of numerous immune cells. Those series of reactions are called the Vroman effect.17 
 
Another literature suggests that the immune response against silicone occurs indirectly, but it still works 
through matrix protein. Hydrophobic materials, such as silicone breast implant is wrapped by the host’s 
protein within hours after attachment with at least 70% will have been wrapped in 1 hour. In general, 
inflammatory cells never have any direct contact with silicone biopolymer, but they do have contact 
through plasma protein, such as IgG, albumin, fibronectin and complement components.11,17  
 
Another study has reported that inflammatory cells that have penetrated into the tissue do not have 
any response to the silicone material itself, but with plasma protein matrix that has specific receptors 
for neutrophils and macrophage. In in vitro study using blood culture with silicone stimulation that 
aimed to evaluate the mechanism of action of lymphocytes, the results showed that there was no 
significant difference with RPMI (negative control); it seems that silicone requires protein to induce the 
development of immune response. These facts are consistent with the results of A Harlim study that 
reported silicone has non-immunogenic properties. 18 
 
Results of examination have provided evidences that there was no difference of IDO enzyme between 
those in RPMI blood culture supernatant and those with PHA-stimulated lymphocytes (positive control) 
or silicone in the normal control group and the granuloma. It could be understood since IDO does not 
act on lymphocytes, but on APC or dendritic cells. 19   
TNF-α level in RPMI blood culture supernatant in the normal group was significantly different from 
those in the granuloma group (Table 2). Although the other cytokines were not significantly different, 
but the levels of proinflammatory cytokines, TNF-α and IFN-γ, were always higher in the  granuloma 
group than the normal group; therefore, in the granuloma group with silicone antigen always have 
inflammatory process.  
With further notice, we found that regarding the levels of TNF-α, IFN-γ and IL-10 cytokines, there was 
higher increase in granuloma group than the normal control group. The increase in normal group was 
only approximately 8 folds for TNF-α, IL-10 PHA; but in contrast, in granuloma group, the increase of 
TNF-α was up to 14 folds, for IL-10, it was approximately 10 folds. IFN-γ in the normal group only had 
an increase of approximately 4 folds; however, in the granuloma group, it increased up to 39 folds. It 
can be understood since PHA will stimulate lymphocytes and IFN-γ cytokines, particularly produced by 
lymphocytes.20,21 In silicone blood culture, the levels of IDO enzyme in granuloma group were 
significantly different from the normal group, i.e. the level of IDO enzyme in granuloma group was 
lower than the normal group (Table 2). It indicates that in patients with granuloma on their skin due 
to silicone injections, there is increased pro-inflammatory cytokines, which is not followed by any 
increase of anti-inflammatory cytokines.  
The development of granuloma is affected by proinflammatory cytokines, i.e. TNF-α and body 
compensation (tolerance), which is carried out by the role of IDO enzyme and IL-10 (anti-inflammatory 
agent). The TNF-α/IL-10 and TNF-α/IDO ratios may show the balance of cytokines in granuloma and 
the function of Treg cells (in the blood specimens, they were not evaluated). 
It can be proven by comparing the levels of proinflammatory cytokines and anti-inflammatory cytokines, 
i.e. TNF-α/IL-10 and TNF-α/IDO ratios, which obviously showed significant difference between the 
normal and granuloma groups. Granuloma group had a higher level of ratio than the normal group. 
(Table 2) 
Other cytokines, although they were not significant, but we could see that there was an increase of 
other cytokines levels in granuloma group, but no increase in the normal group. It could be understood 
since there is a memory on lymphocytes of patients with granuloma who had received silicone injection. 
The developed memory does not occur on the silicone, but on the protein tangled on the silicone. The 
issue has been discussed before and it is consistent with the findings in Anderson study. 22 
 
 
PREDICTION ANALYSIS ON THE DEVELOPMENT OF GRANULOMA BASED ON CYTOKINES 
LEVELS IN BLOOD CULTURE SUPERNATANT  
By evaluating the occurring inflammation and comparing body capability to fight in the form of 
developing anti-inflammatory agent or tolerance capacity, which are represented by IL-10 and IDO, we 
can use TNF-α/IL-10 and TNF-α /IDO ratios to predict the development of granuloma. The correlation 
of TNF-a/IL-10 and TNF-a/IDO with duration of developing symptoms can be seen in Table 3. Results 
of calculation that were found could be used as prediction showed that of the blood specimen, they 
were TNF-a/IL-10 and TNF-a/IDO ratios in the RPMI blood culture supernatant. All results showed 
inverse correlations, which means that the lower the ratio, the patients have more delayed or later visit 
to medical service or the slower the development of granuloma symptoms. (Figure 1). 
 
In Table 2, it is obvious that there was a significant difference of silicone levels between the normal 
and granuloma groups. The level of TNF-a/IL10 of blood culture supernatant in the normal group was 
significantly different from those in granuloma group. The level of TNF-a/IDO of blood culture 
supernatant in the normal group was significantly different from those in granuloma group. Based on 
those data, a cut-off could be made about the development of granuloma. The median of cytokine level 
in RPMI blood culture supernatant in the granuloma group could be made as the cut-off limit for 
predicting the development of granuloma. The cut-off of TNF-a/IL10 ratio was 10.6; while for TNF-
a/IDO was 0.3. 
Based on the cut-off, in a normal individual has low IDO secretion or high level of TNF-α/IL-10 and 
TNF-α/IDO ratios in his/her blood, then the development of granuloma symptoms will occur faster 
when he/she received silicone. (Algorithm, figure 2).  
 
Hence, even in normal group, when they received silicone injection, granuloma will develop if they do 
not have high capacity of anti-inflammatory properties or high TNF-a/IL-10 and TNF-a/IDO ratios. 
Based on the calculation of the cut off, which was then correlated with the normal group of the present 
study, we could say that a low TNF-a/IL-10 ratio (below the cut-off value) was found in 18 out of 37 
subjects who had high risk of developing granuloma when they received silicone injection. Regarding 
the results of evaluating TNF-a/IDO ratio, we also found that about 17 out of 37 subjects had a 
tendency of developing granuloma when they received silicone injection. Thus, in normal individuals, 





Figure 2.  Procedural management for silicone injection 
Notes: 
Patients who want to receive silicone injection then recommended to do blood cultured test to observe 
TNF-α, IL-10 and IDO. Assessment is based on the ratio of TNF-α/IL-10 and TNF-α/IDO. If the result 
below the cut-off ratio, patients can receive silicone injection for medical therapy. If ratio of TNF-α/IL-
10 and TNF-α/IDO are above the cut-off points, patients can not receive silicone injections. If ratio of 
TNF-α/IL-10 above the cut-off and TNF-α/IDO below the cut-off points, patients can receive silicone 
injection, but with precaution about granuloma formation. Patients with ratio of TNF-α /IL-10 under the 
cut-off point and TNF-α /IDO above the cut-off point, are not recommended to receive silicone injection. 
A lower limit of cut-off point was determined based on the results of cytokines levels in the RPMI blood 
culture supernatant of normal patients in the form of median value, which is used as the basics 
management of patients who have received silicone injection, i.e. the lower safe limit including TNF-
a/IL-10 ratio of 3.8 and TNF-a/IDO ratio of 0.1. An algorithm of the plan of silicone injection for normal 
patients is presented in Figure 2.  
PRINCIPLES OF THERAPY  
Based on the results of the present study, patients with granuloma due to silicone injection are 
categorized as those with inflammatory diseases. Significant findings on the cytokines of blood culture 
supernatant that can be used for predicting the development of any disorder is TNF-a. In order to 
evaluate body function on the existence of antigens, which is tolerance, IDO or IL-10 can be evaluated 
as it represents the function of Treg cells. Therefore, the study was conducted to develop a prediction 
based on the ratios between TNF-a/IL-10 and TNF-a/IDO. In patients with granuloma due to silicone 






Cut-off point for ratio of TNF-α/IL-10 : 10.6 
and
Cut-off point for ratio of TNF-α/IDO : 0.3 
Ratio of TNF-α/IL-10 <<
Ratio of TNF-α/IDO << 
Can be injected by 
silicone
but medical grade
Ratio of TNF-α/IL-10 >>
Ratio of TNF-α/IDO <<
Can be injected by 
silicone with warning
Ratio of TNF-α/IL-10 <<
Ratio of TNF-α/IDO >>
Not recommended
Ratio of TNF-α/IL-10>>
Ratio of  TNF-α/IDO >>
Do not receive 
silicone injection
Principles of therapy for patients with granuloma due to silicone injection include preventing the 
development of inflammation since it will cause extensive damage. Evacuating silicone injection-induced 
granuloma should be performed since the liquid silicone in the tissue has persistent characteristic and 
it will continuously induce immune response.  
 
Results of our study have demonstrated that pro-inflammatory cytokine (TNF-a) has a tremendous role 
on inflammation; while on the contrary, anti-inflammatory cytokines levels (IL-10 and IDO) were found 
to decrease in patients with granuloma due to silicone injection (Table 2).  
TNF-a level in blood culture supernatant has systemic characteristics, which can be used for predicting 
the severity of ongoing inflammation. Anti TNF-a agents can be recommended as a therapy to treat 
the ongoing inflammation and it can be a supplement therapy following evacuation procedure as not 
all of the existing silicone and be fully removed and the remaining silicone may cause recurrent 
inflammation.  
 
Some case reports have suggested that to treat silicone induced granuloma, the following treatment 
can be used, i.e. intralesion injection of  Triamcinolone at the dose of 15-20 mg/cc every two months, 
topical treatment of Pimecrolimus twice daily for 3 months, topical  Imiquimod cream for 8 weeks as 
well as oral treatment of minocycline, allopurinol and oral prednisone of 30 mg/day. 23,24 Results of 
those therapies are still less than satisfying; however, Triamsinolone intralesion injection has 
significantly improved the ongoing inflammation. Etanercept, which acts on TNF-a receptor and Fc - 
IgG1 binding, has been reported to have a good result for treating silicone granuloma.9,25,26 The 
treatment at the dose of 50 mg twice weekly or 25 mg subcutaneously twice weekly has provided 
relatively satisfying results.26 Further studies are required to discover therapy or drug treatment that 
can suppress TNF-a cytokines in patients with silicone-induced granuloma or as a therapy to improve 
body tolerance.  
 
Imunomodulators are certain substances that can restore and improve immune system dysfunction or 
that can suppress its excessive function. Herbal drugs such as Centella asiatica, extracts of Echinacea, 
Pyllanthus sp., have been reported to have anti-inflammatory, analgetic and antiviral effects. Therefore, 
further studies are required to evaluate therapy for silicone granuloma.27 
 
5. Conclusions 
1. Level of proinflammatory cytokines tend to be higher in patients with granuloma due to silicone 
injection compared to the normal patients, while anti inflammatory cytokines levels of blood cultured 
supernatant tend to be lower than normal patients.  
2. Level of TNF-α in supernatant of  blood culture can be used as predictor to assess the immune 
response due to silicone injection. The ratio of TNF-α/IL-10 and TNF-α/IDO in supernatant of blood 
culture can be used as predictors for granuloma formation.  
3. The present study can become the basic immune response on the development of silicone 
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